219 related articles for article (PubMed ID: 26830617)
1. PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study.
Turkbey B; Lindenberg ML; Adler S; Kurdziel KA; McKinney YL; Weaver J; Vocke CD; Anver M; Bratslavsky G; Eclarinal P; Kwarteng G; Lin FI; Yaqub-Ogun N; Merino MJ; Linehan WM; Choyke PL; Metwalli AR
Abdom Radiol (NY); 2016 Jan; 41(1):109-18. PubMed ID: 26830617
[TBL] [Abstract][Full Text] [Related]
2. Biodistribution and radiation dosimetry of the carbonic anhydrase IX imaging agent [(18) F]VM4-037 determined from PET/CT scans in healthy volunteers.
Doss M; Kolb HC; Walsh JC; Mocharla VP; Zhu Z; Haka M; Alpaugh RK; Chen DY; Yu JQ
Mol Imaging Biol; 2014 Oct; 16(5):739-46. PubMed ID: 24696183
[TBL] [Abstract][Full Text] [Related]
3. Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma.
Zhu W; Li X; Zheng G; Bai C; Ji Z; Zhang H; Xing H; Zhang Y; Huo L
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3116-3125. PubMed ID: 37246998
[TBL] [Abstract][Full Text] [Related]
4. FDG PET/CT and CT Findings of Renal Cell Carcinoma With Sarcomatoid Differentiation.
Zhu H; Zhao S; Zuo C; Ren F
AJR Am J Roentgenol; 2020 Sep; 215(3):645-651. PubMed ID: 32755159
[No Abstract] [Full Text] [Related]
5. Positron Emission Tomography/Computed Tomography with
Hekman MCH; Rijpkema M; Aarntzen EH; Mulder SF; Langenhuijsen JF; Oosterwijk E; Boerman OC; Oyen WJG; Mulders PFA
Eur Urol; 2018 Sep; 74(3):257-260. PubMed ID: 29730017
[TBL] [Abstract][Full Text] [Related]
6. [(18)F]VM4-037 MicroPET Imaging and Biodistribution of Two In Vivo CAIX-Expressing Tumor Models.
Peeters SG; Dubois L; Lieuwes NG; Laan D; Mooijer M; Schuit RC; Vullo D; Supuran CT; Eriksson J; Windhorst AD; Lambin P
Mol Imaging Biol; 2015 Oct; 17(5):615-9. PubMed ID: 25708744
[TBL] [Abstract][Full Text] [Related]
7. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
[TBL] [Abstract][Full Text] [Related]
8. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma.
Muselaers CH; Boerman OC; Oosterwijk E; Langenhuijsen JF; Oyen WJ; Mulders PF
Eur Urol; 2013 Jun; 63(6):1101-6. PubMed ID: 23453421
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation.
Ferda J; Ferdova E; Hora M; Hes O; Finek J; Topolcan O; Kreuzberg B
Anticancer Res; 2013 Jun; 33(6):2665-72. PubMed ID: 23749925
[TBL] [Abstract][Full Text] [Related]
10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
11. A Microdosing Study with
Kulterer OC; Pfaff S; Wadsak W; Garstka N; Remzi M; Vraka C; Nics L; Mitterhauser M; Bootz F; Cazzamalli S; Krall N; Neri D; Haug AR
J Nucl Med; 2021 Mar; 62(3):360-365. PubMed ID: 32680925
[No Abstract] [Full Text] [Related]
12. Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study.
Hekman MC; Rijpkema M; Muselaers CH; Oosterwijk E; Hulsbergen-Van de Kaa CA; Boerman OC; Oyen WJ; Langenhuijsen JF; Mulders PF
Theranostics; 2018; 8(8):2161-2170. PubMed ID: 29721070
[TBL] [Abstract][Full Text] [Related]
13. Head-to-head comparison of [
Wang G; Li L; Wang J; Zang J; Chen J; Xiao Y; Fan X; Zhu L; Kung HF; Zhu Z
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1499-1509. PubMed ID: 36600099
[TBL] [Abstract][Full Text] [Related]
14. PET/CT with (124)I-cG250: great potential and some open questions.
Khandani AH; Rathmell WK; Wallen EM; Ivanovic M
AJR Am J Roentgenol; 2014 Aug; 203(2):261-2. PubMed ID: 25055257
[TBL] [Abstract][Full Text] [Related]
15. ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice.
Stillebroer AB; Franssen GM; Mulders PF; Oyen WJ; van Dongen GA; Laverman P; Oosterwijk E; Boerman OC
Cancer Biother Radiopharm; 2013 Sep; 28(7):510-5. PubMed ID: 23697926
[TBL] [Abstract][Full Text] [Related]
16. [64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma.
Minn I; Koo SM; Lee HS; Brummet M; Rowe SP; Gorin MA; Sysa-Shah P; Lewis WD; Ahn HH; Wang Y; Banerjee SR; Mease RC; Nimmagadda S; Allaf ME; Pomper MG; Yang X
Oncotarget; 2016 Aug; 7(35):56471-56479. PubMed ID: 27437764
[TBL] [Abstract][Full Text] [Related]
17. [Malignant tumor with false negative 18F-FDG PET image].
Dong MJ; Lin XT; Zhao J; Guan YH; Zuo CT; Chen X; Dai JZ; Jiang BD
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):713-7. PubMed ID: 17274383
[TBL] [Abstract][Full Text] [Related]
18. Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib.
Khandani AH; Cowey CL; Moore DT; Gohil H; Rathmell WK
Nucl Med Commun; 2012 Sep; 33(9):967-73. PubMed ID: 22714005
[TBL] [Abstract][Full Text] [Related]
19. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT.
Rowe SP; Gorin MA; Hammers HJ; Som Javadi M; Hawasli H; Szabo Z; Cho SY; Pomper MG; Allaf ME
Ann Nucl Med; 2015 Dec; 29(10):877-82. PubMed ID: 26286635
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of renal cell carcinoma histological subtype and fuhrman grade using
Nakajima R; Nozaki S; Kondo T; Nagashima Y; Abe K; Sakai S
Eur Radiol; 2017 Nov; 27(11):4866-4873. PubMed ID: 28523353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
